The estimated Net Worth of Junli He is at least 948 千$ dollars as of 12 December 2022. Junli He owns over 135 units of Biostage stock worth over 947,050$ and over the last 3 years Junli sold BSTG stock worth over 922$.
Junli has made over 1 trades of the Biostage stock since 2022, according to the Form 4 filled with the SEC. Most recently Junli sold 135 units of BSTG stock worth 922$ on 12 December 2022.
The largest trade Junli's ever made was selling 135 units of Biostage stock on 12 December 2022 worth over 922$. On average, Junli trades about 27 units every 0 days since 2021. As of 12 December 2022 Junli still owns at least 235,000 units of Biostage stock.
You can see the complete history of Junli He stock trades at the bottom of the page.
Junli's mailing address filed with the SEC is 84 OCTOBER HILL RD, SUITE 11, HOLLISTON, MA, 01746.
Over the last 8 years, insiders at Biostage have traded over 962,849$ worth of Biostage stock and bought 1,593,581 units worth 3,804,230$ . The most active insiders traders include David Green、Capital Llc Dst、Ronald J Packard. On average, Biostage executives and independent directors trade stock every 79 days with the average trade being worth of 217,604$. The most recent stock trade was executed by Capital Llc Dst on 6 April 2023, trading 62,500 units of BSTG stock currently worth 375,000$.
Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
Biostage executives and other stock owners filed with the SEC include: